Bioventus Inc. (BVS) 当前追踪市盈率 (P/E) 为 26.2, 前瞻市盈率为 14.1. 追踪盈利收益率为 3.82%, 前瞻盈利收益率 7.11%. PEG 0.11 (Peter Lynch 低估标准 ≤1.0). 格雷厄姆数为 $5.13.
本页证实的标准:
SharesGrow 综合评分： 52/100 其中 3/7 项标准通过。
| Year | P/E (TTM) | PEG 比率 | P/B 比率 | P/S 比率 | 股息收益率 |
|---|---|---|---|---|---|
| 2016 | -60.8 | 1.13 | 0.00 | 3.98 | - |
| 2017 | -666.0 | 7.32 | 0.00 | 3.74 | - |
| 2018 | -89.4 | -0.13 | 7.51 | 3.42 | 0.72% |
| 2019 | 159.3 | -1.03 | 7.63 | 3.21 | 0.84% |
| 2020 | 44.1 | 0.17 | 5.09 | 2.25 | 2.75% |
| 2021 | 34.0 | -0.25 | 1.44 | 1.53 | 0.06% |
| 2022 | -1.0 | 0.00 | 0.49 | 0.31 | - |
| 2023 | -2.1 | 0.55 | 1.90 | 0.64 | - |
| 2024 | -20.5 | 0.26 | 4.64 | 1.20 | - |
| 2025 | 21.8 | -0.13 | 2.69 | 0.87 | - |
| Year | EPS（稀释） | 营收 | 净利润 | 净利润率 |
|---|---|---|---|---|
| 2016 | $-0.32 | $274.5M | $-17.95M | -6.5% |
| 2017 | $-0.03 | $292.06M | $-1.64M | -0.6% |
| 2018 | $-0.22 | $319.18M | $-12.21M | -3.8% |
| 2019 | $0.12 | $340.14M | $6.85M | 2% |
| 2020 | $0.44 | $321.16M | $16.41M | 5.1% |
| 2021 | $-0.15 | $430.9M | $19.38M | 4.5% |
| 2022 | $-2.59 | $512.12M | $-158.7M | -31% |
| 2023 | $-2.49 | $512.35M | $-156.23M | -30.5% |
| 2024 | $-0.75 | $573.28M | $-33.54M | -5.9% |
| 2025 | $0.33 | $568.09M | $22.73M | 4% |
| Year | EPS（平均） | EPS 范围 | 营收（平均） | 营收范围 | 分析师人数 |
|---|---|---|---|---|---|
| 2026 | $0.75 | $0.55 – $0.86 | $604.75M | $602.8M – $606.69M | 3 |
| 2027 | $0.88 | $0.85 – $0.90 | $647.43M | $639.57M – $655.28M | 3 |
| 2028 | $1.02 | $0.88 – $1.16 | $687.21M | $687.2M – $687.22M | 2 |
| 2029 | $1.08 | $1.07 – $1.09 | $738.77M | $733.18M – $744.76M | 1 |
| 2030 | $1.22 | $1.21 – $1.23 | $794.93M | $788.92M – $801.39M | 1 |
